Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists
about
Hypoxia-inducible factors as molecular targets for liver diseasesαβ TCR-mediated recognition: relevance to tumor-antigen discovery and cancer immunotherapyA2aR antagonists: Next generation checkpoint blockade for cancer immunotherapyBlockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma.Prelude to oral microbes and chronic diseases: past, present and futureActivation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression.Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacyAlternative splicing of human NT5E in cirrhosis and hepatocellular carcinoma produces a negative regulator of ecto-5'-nucleotidase (CD73).CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma.Immunological mechanisms of the antitumor effects of supplemental oxygenation.Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma modelCAR T-cell immunotherapy: The path from the by-road to the freeway?A2A adenosine receptors control pancreatic dysfunction in high-fat-diet induced obesity.CD73-adenosine: a next-generation target in immuno-oncology.Cancer Immunotherapy: Selected Targets and Small-Molecule Modulators.Potential Therapeutic Applications of Adenosine A2A Receptor Ligands and Opportunities for A2A Receptor Imaging.A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer.Myeloid-derived suppressor cells and tumor escape from immune surveillance.The Sabotaging Role of Myeloid Cells in Anti-Angiogenic Therapy: Coordination of Angiogenesis and Immune Suppression by Hypoxia.The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.Targeting adenosine in cancer immunotherapy: a review of recent progress.Potassium channels of T lymphocytes take center stage in the fight against cancer.Oxygenation to improve cancer vaccines, adoptive cell transfer and blockade of immunological negative regulators.Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor-Host Interaction and Therapeutic Perspectives.Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.Adenosine metabolism, immunity and joint health.Prostaglandin E2-mediated adenosinergic effects on CD14+ cells: Self-amplifying immunosuppression in cancer.Hypoxia-Driven Adenosine Accumulation: A Crucial Microenvironmental Factor Promoting Tumor Progression.Targeting the Adenosinergic Axis in Chronic Lymphocytic Leukemia: A Way to Disrupt the Tumor Niche?Increased vessel perfusion predicts the efficacy of immune checkpoint blockade.A defect in KCa3.1 channel activity limits the ability of CD8+ T cells from cancer patients to infiltrate an adenosine-rich microenvironment.Recovery from experimental autoimmune uveitis promotes induction of antiuveitic inducible Tregs.Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors.The role of hypoxia in shaping the recruitment of proangiogenic and immunosuppressive cells in the tumor microenvironment.Nanobody-Based Biologics for Modulating Purinergic Signaling in Inflammation and Immunity.Adenosine A2A Receptor Antagonists in Neurodegenerative Diseases: Huge Potential and Huge Challenges.Targeting adenosine for cancer immunotherapy.Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment
P2860
Q26752304-1B5A6B61-E1D1-4F9E-9843-6B279856669BQ26861133-DFB9389A-BF36-4A21-8EF8-E2EAB99C3021Q28087576-C54433C5-A1EB-425E-B4E6-52757FDBF422Q33771631-E2DA0F80-A112-462E-B6CE-A6171AA81F11Q34468829-09AC600D-5E31-40C8-BA1B-1FE8732D8630Q34539323-10298A4E-7B02-46D1-8659-F1AA4B566C95Q34550649-1A5BD706-232A-4325-BADF-8D3C11B91FB4Q34680354-5ED3C089-01B0-4C3C-9C20-0775FACFD240Q35941350-65E315F1-06F0-4553-A183-8D2EA00A114EQ36269330-A7CE7F36-FED9-458F-9E60-513774CC5396Q36413809-FAC63BCA-46E4-4A96-B6E7-14027BC7811FQ38632105-E51ED538-B816-4431-82A1-48BAF9550633Q38648091-10D66720-F95B-4A04-9FF1-224F5F3CDF5BQ38711094-D48D8EFF-D8DF-4BA5-A1C6-9054E2FCED30Q38719858-62516176-440C-493E-9DEC-7957F165FCE7Q38765118-6B228341-C55D-410D-AFED-C246247302A2Q38900954-11E0220E-8510-4CAA-A743-E710F297076FQ38992562-AFFF0AE8-3B8F-43B5-8DFD-F69454542683Q39034031-5363E410-A31E-4C2A-B658-E8E77D1B8394Q39161005-6E4F7B02-2D72-4DAC-B1B6-4CBE17CA5C0CQ39235260-DC61AB1E-669D-4ECC-A0F4-990C4E8D187AQ42330136-00B44F1F-24CB-4091-9897-6B96AC367ED4Q43185256-33D5D554-022B-4FBF-8AC2-721EC99F8065Q46026307-3A69C6DD-3E3B-4A02-87AF-79142FAF7785Q47395423-5EDBF414-048E-41A6-B2C2-9166AC829B36Q50086989-EED40640-AD80-4F47-BA6A-8D1E6398655DQ51084411-FB073206-E60E-4EF0-9113-55613F8101D4Q51554659-E60B3EFF-E2D1-4170-92DF-E6778A5DF74DQ52323624-C8593FB4-4273-4CC5-B0D0-DF8C05E0C8C1Q52583527-62FB372A-E51A-4DEB-A4A5-CE147E90C672Q52716939-2C4BD414-3F20-480B-847B-AAB8A1A3ADF9Q53543423-4AC4DAB3-6E96-4A1B-8C91-0B23266586F1Q54986388-4835CD10-F4FD-4506-B729-7798F76164D8Q55019858-66577D4A-BDF1-40BC-9D6A-91EACACE9277Q55025877-5C7BF617-614D-4C6F-A1E3-45DC8307B2E0Q55297865-D32A902B-3B34-41D1-8DA8-A09588AC8B1CQ55330380-D6BE9266-427D-43C9-9563-09E8C569DE21Q57483703-2D0D3210-60B8-4360-BDCC-628968DFC442
P2860
Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Hostile, hypoxia-A2-adenosiner ...... ercome for tumor immunologists
@ast
Hostile, hypoxia-A2-adenosiner ...... ercome for tumor immunologists
@en
type
label
Hostile, hypoxia-A2-adenosiner ...... ercome for tumor immunologists
@ast
Hostile, hypoxia-A2-adenosiner ...... ercome for tumor immunologists
@en
prefLabel
Hostile, hypoxia-A2-adenosiner ...... ercome for tumor immunologists
@ast
Hostile, hypoxia-A2-adenosiner ...... ercome for tumor immunologists
@en
P2093
P2860
P1476
Hostile, hypoxia-A2-adenosiner ...... ercome for tumor immunologists
@en
P2093
Bryan Belikoff
Dmitriy Lukashev
Michail V Sitkovsky
Robert Abbott
Stephen Hatfield
P2860
P304
P356
10.1158/2326-6066.CIR-14-0075
P577
2014-07-01T00:00:00Z